Literature DB >> 2970910

Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.

R L Chan1, M R Henzl, M E LePage, J LaFargue, C A Nerenberg, S Anik, M D Chaplin.   

Abstract

Nafarelin, a potent gonadotropin-releasing hormone (GnRH) agonist, was absorbed rapidly into systemic circulation (time to reach peak concentration, 20 to 40 minutes) after intranasal but not after sublingual or vaginal administration. Serum elimination half-life was about 2 hours. Nasal absorption of nafarelin was increased by increasing the concentration of the drug in the dose solution and incorporating sodium glycocholate into the nasal formulation. An optimal formulation providing maximum nasal absorption of nafarelin was one containing 1.75 mg nafarelin per ml and 2% sodium glycocholate. Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%. The metabolism and excretion of nafarelin were determined in three subjects after subcutaneous administration of [14C]-nafarelin. Radioactivity was excreted in approximately equal amounts in urine and stool. Six metabolites accounted for most of the radioactivity in urine. Four metabolites were short peptide fragments of nafarelin and the other metabolites were naphthylalanine and 2-naphthylacetic acid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970910     DOI: 10.1038/clpt.1988.150

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Percutaneous absorption enhancement of leuprolide.

Authors:  M Y Lu; D Lee; G S Rao
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

3.  Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies.

Authors:  K S Bhatia; J Singh
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

4.  Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans.

Authors:  A Adjei; D Sundberg; J Miller; A Chun
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

Review 5.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 6.  A risk benefit assessment of drugs used in the treatment of endometriosis.

Authors:  R W Shaw
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.